Life sciences firm harnesses AI expertise in fight against cancer
Life sciences company, Avacta Therapeutics, has entered into a collaboration with Tempus AI Inc, a technology company which has adopted artificial intelligence to advance precision medicine and patient care.
The partnership will give Wetherby-based Avacta access to Tempus’s datasets comprising primary tumour samples and associated clinical data from over 200,000 patients.
Avacta says it plans to use insights from this data to further enhance its own pre|CISION® cancer medication platform by identifying patient populations for its clinical programs.
Tempus’s analytical support and computational biology experts will collaborate in the data analysis with the Avacta team.
Christina Coughlin, CEO of Avacta, said: “The Tempus AI real-world database and industry-leading AI capabilities will enable us to better assess the specific patient population most likely to respond to our pre|CISION® therapies, enabling faster, smarter clinical development with the highest probability of success.”
Kate Sasser, chief scientific officer at Tempus AI, added: “A powerful use of AI in drug development is leveraging real-world data to have a deeper understanding of the patient populations that would benefit from a specific mechanism of action.
“Tempus was created to build one of the world’s largest libraries of multimodal data and an operating system to make those data accessible and useful.
“This partnership with Avacta is another example of our execution of that vision, and we are thrilled to partner with Avacta in support of their efforts to bring game-changing new therapies to patients in need.”
